Research programme: fms-like tyrosine kinase 3/cyclin dependent kinase 4 inhibitors - AmgenAlternative Names: AM-5992; flt3/CDK4 dual kinase inhibitor - Amgen
Latest Information Update: 31 Oct 2013
At a glance
- Originator Amgen
- Class Small molecules
- Mechanism of Action Cyclin-dependent kinase 4 inhibitors; Fms-like tyrosine kinase 3 inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Acute myeloid leukaemia